At a crossroads: coronavirus disease 2019 recovery and the risk of pulmonary vascular disease

Thomas M. Cascino, Ankit A. Desai, Yogendra Kanthi

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Purpose of reviewThe coronavirus disease 2019 (COVID-19) pandemic has led to almost 3,000,000 deaths across 139 million people infected worldwide. Involvement of the pulmonary vasculature is considered a major driving force for morbidity and mortality. We set out to summarize current knowledge on the acute manifestations of pulmonary vascular disease (PVD) resulting from COVID-19 and prioritize long-term complications that may result in pulmonary hypertension (PH).Recent findingsAcute COVID-19 infection can result in widespread involvement of the pulmonary vasculature, myocardial injury, evidence of persistent lung disease, and venous thromboembolism. Post COVID-19 survivors frequently report ongoing symptoms and may be at risk for the spectrum of PH, including group 1 pulmonary arterial hypertension, group 2 PH due to left heart disease, group 3 PH due to lung disease and/or hypoxia, and group 4 chronic thromboembolic PH.SummaryThe impact of COVID-19 on the pulmonary vasculature is central to determining disease severity. Although the long-term PVD manifestations of COVID-19 are currently uncertain, optimizing the care of risk factors for PH and monitoring for the development of PVD will be critical to reducing long-term morbidity and improving the health of survivors.

Original languageEnglish (US)
Pages (from-to)342-349
Number of pages8
JournalCurrent opinion in pulmonary medicine
Issue number5
StatePublished - Sep 1 2021


  • coronavirus disease 2019
  • pulmonary embolism
  • pulmonary hypertension
  • pulmonary vascular disease

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'At a crossroads: coronavirus disease 2019 recovery and the risk of pulmonary vascular disease'. Together they form a unique fingerprint.

Cite this